LONG-TERM DRUG SURVIVAL OF ETANERCEPT VS OTHER TNF INHIBITOR THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Emery, P. [1 ]
Vlahos, B. [2 ]
Szczypa, P. [3 ]
Thakur, M. [4 ]
Jones, H. E. [2 ]
Woolcott, J. [2 ]
Estrella, P. V. Santos [2 ]
Gibofsky, A. [5 ]
Rolland, C. [6 ]
Citera, G. [7 ]
Marshall, L. [2 ]
机构：
[1] Leeds Inst Rheumat & Musculoskeletal Med, Leeds Musculoskeletal Biomed Res Ctr LTHT, Leeds, W Yorkshire, England
[2] Pfizer, Collegeville, PA USA
[3] Pfizer Ltd, Walton Oaks, GA USA
[4] Pfizer, Sandwich, Kent, England
[5] Weill Med Coll, New York, NY USA
[6] Envis Pharma Grp, Horsham, W Sussex, England
[7] Consultorios Reumatol, Buenos Aires, DF, Argentina
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2504
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0460
引用
收藏
页码：1391 / 1392
页数：3
相关论文
共 50 条
  • [41] Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
    Minden, Kirsten
    Niewerth, Martina
    Klotsche, Jens
    Hammer, Michael
    Haas, Johannes Peter
    Ganser, Gerd
    Horneff, Gerd
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S493 - S493
  • [42] Long-term safety of abatacept in patients with rheumatoid arthritis
    Atzeni, Fabiola
    Sarzi-Puttini, Piercarlo
    Mutti, Alessandra
    Bugatti, Serena
    Cavagna, Lorenzo
    Caporali, Roberto
    AUTOIMMUNITY REVIEWS, 2013, 12 (12) : 1115 - 1117
  • [43] Long-term persistence with rituximab in patients with rheumatoid arthritis
    Oldroyd, Alexander G. S.
    Symmons, Deborah P. M.
    Sergeant, Jamie C.
    Kearsley-Fleet, Lianne
    Watson, Kath
    Lunt, Mark
    Hyrich, Kimme L.
    RHEUMATOLOGY, 2018, 57 (06) : 1089 - 1096
  • [44] Serum levels of cartilage oligomeric matrix protein during long-term treatment with etanercept in rheumatoid arthritis patients
    Riccieri, V
    Spadero, A
    Scrivo, R
    Germano, V
    Magrini, L
    Valesini, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 472 - 472
  • [45] Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis
    Klareskog, L.
    Gaubitz, M.
    Rodriguez-Valverde, V.
    Malaise, M.
    Dougados, M.
    Wajdula, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 238 - 247
  • [46] LONG-TERM SAFETY OF NON-TNF INHIBITOR BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS WITH CHRONIC OR PAST HEPATITIS B VIRUS INFECTION
    Koutsianas, C.
    Thomas, K.
    Hadziyannis, E.
    Makris, A.
    Lazarini, A.
    Vassilopoulos, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 845 - 846
  • [47] Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNF alpha Drug
    Rajakulendran, Shyra
    Deighton, Chris
    CURRENT DRUG SAFETY, 2006, 1 (03) : 259 - 264
  • [48] THE PARADOX OF EFFECTIVE THERAPIES BUT POOR LONG-TERM OUTCOMES IN RHEUMATOID-ARTHRITIS
    PINCUS, T
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1992, 21 (06) : 2 - 15
  • [49] A Retrospective Study to Evaluate the Efficacy, Safety, and Drug Survival of Etanercept in Elderly Patients with Rheumatoid Arthritis
    Shah, Alpesh
    Deamude, Melissa
    Mech, Cynthia
    McMurray, Judi
    Bensen, Robert
    Bensen, William
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 959 - 959
  • [50] LONG-TERM TREATMENT WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN RHEUMATOID-ARTHRITIS - A PROSPECTIVE DRUG SURVIVAL STUDY
    WIJNANDS, M
    VANRIEL, P
    VANTHOF, M
    GRIBNAU, F
    VANDEPUTTE, L
    JOURNAL OF RHEUMATOLOGY, 1991, 18 (02) : 184 - 187
12345